Anatomical main group
R – RESPIRATIONSTRAKT
71Decisions
93Patient groups
Added benefit by patient group
- Major5
- Considerable8
- Minor8
- Non-quantifiable18
- Not proven53
- Lesser benefit1
Subgroups
- R01 RHINOLOGIKA 1 decision
- R03 MITTEL BEI OBSTRUKTIVEN ATEMWEGSERKRANKUNGEN 22 decisions
- R07 ANDERE MITTEL FÜR DEN RESPIRATIONSTRAKT 48 decisions
Decisions, newest first
- 2026-10-01ExdensurDepemokimabNot proven
- 2026-10-01ExdensurDepemokimabNot proven: 2 of 2 patient groups
- 2026-09-03NucalaMepolizumabNot proven
- 2026-05-07TezspireTezepelumabNon-quantifiable
- 2025-10-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2025-10-16KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor: 1 of 3 patient groupsConsiderable: 1 of 3 patient groupsNon-quantifiable: 1 of 3 patient groups
- 2025-05-15FasenraBenralizumabNot proven: 2 of 2 patient groups
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2024-01-18OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2023-06-01RyaltrisOlopatadin/MometasonNot proven
- 2023-05-12TezspireTezepelumabNot proven: 2 of 2 patient groups
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNon-quantifiable
- 2022-08-04KalydecoIvacaftorConsiderable
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorConsiderable
- 2022-05-19NucalaMepolizumabConsiderable
- 2022-05-19NucalaMepolizumabNot proven
- 2022-05-19NucalaMepolizumabNot proven
- 2022-03-18OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-05-20KalydecoIvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNon-quantifiable
- 2021-05-20SymkeviTezacaftor/IvacaftorNot proven
- 2021-05-20SymkeviTezacaftor/IvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNon-quantifiable
- 2021-02-18KalydecoIvacaftorMajor
- 2021-02-18KalydecoIvacaftorMajor
- 2021-02-18KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor
- 2021-02-18KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor
- 2021-02-04Enerzair BreezhalerIndacaterol/Glycopyrronium/MometasonNot proven
- 2020-12-17KalydecoIvacaftorNon-quantifiable: 2 of 2 patient groups
- 2020-12-17SymkeviTezacaftor/IvacaftorNot proven
- 2020-12-17SymkeviTezacaftor/IvacaftorNot proven
- 2020-06-04KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorMinor
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorNot proven
- 2020-02-20KalydecoIvacaftorNot proven
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2019-05-02Trelegy ElliptaFluticasonfuroat/Umeclidinium/VilanterolNot proven
- 2019-03-22NucalaMepolizumabNot proven
- 2018-08-16Trelegy ElliptaFluticasonfuroat/Umeclidinium/VilanterolNot proven
- 2018-08-02FasenraBenralizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-08-02OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2017-07-06CinqaeroReslizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-07-21NucalaMepolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-07-21Incruse Ellipta (previously Incruse)UmeclidiniumNot proven: 2 of 2 patient groups
- 2016-06-02OrkambiLumacaftor/IvacaftorConsiderable
- 2016-04-07Bretaris GenuairAclidiniumbromidConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2016-02-04Spiolto Respimat Olodaterol/TiotropiumMinor: 1 of 2 patient groupsLesser benefit: 1 of 2 patient groups
- 2015-07-16Brimica GenuairFormoterol/AclidiniumbromidConsiderable: 1 of 4 patient groupsMinor: 1 of 4 patient groupsNot proven: 2 of 4 patient groups
- 2015-01-08Anoro ElliptaUmeclidinium/VilanterolNot proven: 2 of 2 patient groups
- 2014-05-08Ultibro BreezhalerIndacaterol/GlycopyrroniumMinor: 2 of 4 patient groupsNot proven: 2 of 4 patient groups
Data status: 2026-10-29